In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4474-4476

  Soczo G ^a   Kardos, G ^a   Varga, I ^b   Kelentey, B ^b   Gesztelyi, R ^a   Majoros, L ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA TROPICALIS; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; FUNGAL STRAIN; FUNGUS GROWTH; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA TROPICALIS; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS;

EID: 36749104218     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00880-07     Document Type: Article

References (11)

1. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.
2. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
3. Clemens, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
4. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
5. Majoros, L., G. Kardos, B. Szabó, and M. Sipiczki. 2005. Caspofungin susceptibility testing of Candida inconspicua: correlation of different methods with the minimal fungicide concentration. Antimicrob. Agents Chemother. 49:3486-3488.
6. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Pai, M. P., A. L. Jones, and C. K. Mullen. 2007. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn. Microbiol. Infect. Dis. 58:129-132.
8. Pappas, P. G., C. M. F. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
9. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
10. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
11. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.